These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 8382526)
1. Reduced sensitivity to camptothecin of topoisomerase I from a L5178Y mouse lymphoma subline sensitive to X-radiation. Kowalska-Loth B; Staron K; Buraczewska I; Szumiel I; Kapiszewska M; Lange CS Biochim Biophys Acta; 1993 Feb; 1172(1-2):117-23. PubMed ID: 8382526 [TBL] [Abstract][Full Text] [Related]
2. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases. Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196 [TBL] [Abstract][Full Text] [Related]
3. Effects of topoisomerase I-targeted drugs on radiation response of L5178Y sublines differentially radiation and drug sensitive. Szumiel I; Buraczewska I; Gradzka I; Gasinska A Int J Radiat Biol; 1995 Apr; 67(4):441-8. PubMed ID: 7738407 [TBL] [Abstract][Full Text] [Related]
4. The sensitivity to camptothecin of DNA topoisomerase I in L5178Y-S lymphoma cells. Staron K; Kowalska-Loth B; Szumiel I Carcinogenesis; 1994 Dec; 15(12):2953-5. PubMed ID: 8001262 [TBL] [Abstract][Full Text] [Related]
5. Modulation of the effect of camptothecin in x-irradiated L5178Y-R and L5178Y-S cells by benzamide. Gradzka I; Iwaneńko T; Kruszewski M; Szumiel I; Kapiszewska M; Lange CS; Afanasjev G Radiat Environ Biophys; 1996 Aug; 35(3):185-91. PubMed ID: 8880961 [TBL] [Abstract][Full Text] [Related]
6. Discrepancy between the initial DNA damage and cell survival after camptothecin treatment in two murine lymphoma L5178Y sublines. Gradzka I; Szumiel I Cell Biochem Funct; 1996 Sep; 14(3):163-71. PubMed ID: 8888569 [TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of topoisomerase I in L5178Y-S cells is associated with poly(ADP-ribose) metabolism. Staron K; Kowalska-Loth B; Nieznanski K; Szumiel I Carcinogenesis; 1996 Mar; 17(3):383-7. PubMed ID: 8631120 [TBL] [Abstract][Full Text] [Related]
8. DNA repair, cell cycle progression and cell death following camptothecin treatment in two murine lymphoma L5178Y sublines. Gradzka I; Skierski J; Szumiel I Cell Biochem Funct; 1998 Dec; 16(4):239-52. PubMed ID: 9857486 [TBL] [Abstract][Full Text] [Related]
9. Relationship between topoisomerase II and radiosensitivity in mouse L5178Y lymphoma strains. Evans HH; Ricanati M; Horng MF; Mencl J Mutat Res; 1989 Jan; 217(1):53-63. PubMed ID: 2536134 [TBL] [Abstract][Full Text] [Related]
10. Lowered phosphorylation of topoisomerase I is a direct reason for reduced sensitivity of L5178Y-S cells to camptothecin. Staron K; Kowalska-Loth B; Szumiel I Ann N Y Acad Sci; 1996 Dec; 803():321-3. PubMed ID: 8993529 [No Abstract] [Full Text] [Related]
11. Sensitivity to inhibitors of type II topoisomerases from mouse L5178Y lymphoma strains that are resistant or sensitive to X-radiation. Staron K; Kowalska-Loth B; Szumiel I; Buraczewska I Mutat Res; 1993 Feb; 285(2):175-9. PubMed ID: 7678889 [TBL] [Abstract][Full Text] [Related]
12. Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related naphthoquinones. Frydman B; Marton LJ; Sun JS; Neder K; Witiak DT; Liu AA; Wang HM; Mao Y; Wu HY; Sanders MM; Liu LF Cancer Res; 1997 Feb; 57(4):620-7. PubMed ID: 9044837 [TBL] [Abstract][Full Text] [Related]
13. Topoisomerase I is differently phosphorylated in two sublines of L5178Y mouse lymphoma cells. Staron K; Kowalska-Loth B; Zabek J; Czerwinski RM; Nieznanski K; Szumiel I Biochim Biophys Acta; 1995 Jan; 1260(1):35-42. PubMed ID: 7999792 [TBL] [Abstract][Full Text] [Related]
14. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765 [TBL] [Abstract][Full Text] [Related]
15. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin. Riou JF; Grondard L; Petitgenet O; Abitbol M; Lavelle F Biochem Pharmacol; 1993 Sep; 46(5):851-61. PubMed ID: 8396937 [TBL] [Abstract][Full Text] [Related]
16. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Yamashita Y; Kawada S; Fujii N; Nakano H Biochemistry; 1991 Jun; 30(24):5838-45. PubMed ID: 1646001 [TBL] [Abstract][Full Text] [Related]
17. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Woessner RD; Eng WK; Hofmann GA; Rieman DJ; McCabe FL; Hertzberg RP; Mattern MR; Tan KB; Johnson RK Oncol Res; 1992; 4(11-12):481-8. PubMed ID: 1338578 [TBL] [Abstract][Full Text] [Related]
18. beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. Li CJ; Averboukh L; Pardee AB J Biol Chem; 1993 Oct; 268(30):22463-8. PubMed ID: 8226754 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. Boothman DA; Trask DK; Pardee AB Cancer Res; 1989 Feb; 49(3):605-12. PubMed ID: 2535961 [TBL] [Abstract][Full Text] [Related]
20. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I. Prost S; Riou G Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]